Dr. Marcie Glicksman received her Bachelor’s degree from Brown University in Providence, Rhode Island and her Ph.D. in neuroscience from Washington University in St. Louis, Missouri. (WU is known for Monsanto's global HQ & academic partners)

Dr. Glicksman has been in the field of drug discovery for 18 years, the most recent five in academics and thirteen years in the pharmaceutical/biotech industry, having worked at Cephalon, DuPont - Merck, Cubist (as director of leads discovery), and the start up company, Descartes Therapeutics.

She is currently the senior director of the leads discovery group at the Laboratory for Drug Discovery in Neurodegeneration, which is part of the Harvard NeuroDiscovery Center, and assistant professor in the Neurology Department at Brigham and Women’s Hospital and Harvard Medical School.

Dr. Glicksman was elected in 2005 to the board of directors for the Society for Biomolecular Sciences and served as its chairperson for two years. She is on the science advisory board for the Alzheimer’s disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH and the Michael J. Fox Foundation.

She has extensive experience in assay development, high throughput screening, and chemical databases as well as animal pharmacology and preclinical development. ¹⁾

(Unnamed in Science-org bio) Dr. Marcie Glicksman has been in the drug discovery field for over 20 years, and has extensive experience in assay development, high throughput screening, and chemical databases. Before joining ORIG3N, she was Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN), part of the Harvard NeuroDiscovery Center. She holds a BA from Brown University and a PhD in Neuroscience from Washington University.²⁾